However, there are a few indirect factors worth understanding
Choosing an appropriate needle size is one of the most overlooked yet important decisions when starting subcutaneous GLP-1 therapy
Yes, but always do so under provider supervision
Based on the promising preclinical data, Bunce conducted a small, double-blind, placebo-controlled trial funded by the National Institute on Drug Abuse and Novo Nordisk, the company that makes Ozempic and Wegovy
The SUSTAIN 7 and PIONEER 10 trials did not evaluate hard outcomes such as death or cardiovascular events
[8] [9] Semaglutide's gastrointestinal adverse effects, particularly nausea and vomiting, occur commonly during treatment initiation and dose escalation